Rymph India Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 119.96%
- Profit Growth 119.80%
- Ebitda -155.79%
- Net Worth 27.11%
- Total Assets 211.12%
About Rymph India Biotech
Rymph India Biotech Private Limited (RIBPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 July 2018 (Six years and six months 25 days old ). Its registered office is in Greater Noida, Uttar Pradesh.
The Company is engaged in the Consumer Electronics & Durables Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Yogesh Rajpoot and Muskan Rajpoot serve as directors at the Company.
Company Details
-
LocationGreater Noida, Uttar Pradesh
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909UP2018PTC106362
-
Company No.
106362
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Jul 2018
-
Date of AGM
28 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Rymph India Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yogesh Rajpoot
|
Managing Director | 18-Jul-2018 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Muskan Rajpoot
|
Director | 19-Aug-2022 | Current |
Financial Performance of Rymph India Biotech.
Rymph India Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 119.96% increase. The company also saw a substantial improvement in profitability, with a 119.8% increase in profit. The company's net worth Soared by an impressive increase of 27.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rymph India Biotech?
In 2021, Rymph India Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Rymph Management Services Private LimitedYogesh Rajpoot and Muskan Rajpoot are mutual person
-
Jnv Alumni Association Of Buklana
Yogesh Rajpoot is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rymph India Biotech?
Unlock and access historical data on people associated with Rymph India Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rymph India Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rymph India Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
